NASDAQ$NVCR
Novocure Ltd · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results with commercial strength and strategic investment.
Novocure reported a strong second quarter with net revenues of $133.5 million, a 15% increase compared to Q2 2020, and a gross margin of 79%. The company invested a record $50 million in research and development initiatives. However, the company's net loss was $14.6 million compared to a net income of $1.7 million for the same period in 2020.
- Net revenues reached $133.5 million, a 15% increase year-over-year.
- Gross margin was 79%.
- Invested a record $50 million in research and development.
- FDA approved IDE supplement for the phase 3 pivotal LUNAR trial in non-small cell lung cancer (NSCLC).
Headline financials
Revenue & EPS history
Novocure · Revenue · Quarterly
$134M
Forward guidance
Novocure anticipates several clinical milestones in the coming quarters and years, including interim analyses and data releases from ongoing phase 2 and phase 3 trials in various cancer types. Enrollment timelines for the METIS trial have been delayed by two quarters, with final data now expected in 2023.
Tailwinds
- Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (Q3 2021)
- Data from phase 2 pilot EF-31 trial in gastric cancer (2022)
- Interim analysis of phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2022)
- Data from phase 2 pilot EF-33 trial with high-intensity arrays in recurrent glioblastoma (2022)
- Final data from phase 3 pivotal LUNAR trial in NSCLC (2022)
Headwinds
- Data from phase 3 pivotal METIS trial in brain metastases (2023)
- Final data from phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2023)
- Final data from phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2023)
- Enrollment timelines for our METIS trial are reliant on clinical site expansion in regions that continue to be materially delayed as clinical sites devote significant resources to the COVID-19 global pandemic.
- Anticipate a two-quarter delay in last patient enrollment for METIS, with final data in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+2.6%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+27.5%
Q1 2026
Best reaction
-34.3%
Q2 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +27.5% | +33.1% | +42.8% | |
| Q4 2025 | -7.9% | -11.3% | -26.8% | |
| Q3 2025 | -4.7% | -11.0% | -5.0% | |
| Q2 2025 | -0.3% | +3.9% | +4.6% | |
| Q1 2025 | +4.4% | +2.9% | +4.3% | |
| Q4 2024 | -12.4% | -17.2% | -14.1% | |
| Q3 2024 | -10.1% | -1.8% | +18.7% | |
| Q2 2024 | +1.2% | +24.2% | -4.1% | |
| Q1 2024 | +16.0% | +21.9% | +72.8% | |
| Q4 2023 | -2.6% | +4.4% | -15.4% | |
| Q3 2023 | -10.2% | -5.5% | -11.4% | |
| Q2 2023 | -17.4% | -19.1% | -26.2% | |
| Q1 2023 | +3.5% | +6.2% | +20.6% | |
| Q4 2022 | -6.1% | -6.1% | -30.3% | |
| Q3 2022 | +3.5% | +8.1% | +10.8% | |
| Q2 2022 | -8.1% | -5.1% | +11.9% | |
| Q1 2022 | -0.5% | +8.9% | +9.1% | |
| Q4 2021 | +10.1% | +10.5% | +9.8% | |
| Q3 2021 | -7.4% | -2.8% | -12.4% | |
| Q2 2021 | -15.3% | -18.0% | -25.9% | |
| Q1 2021 | -0.7% | -4.0% | -0.7% | |
| Q4 2020 | -13.9% | -11.6% | -28.1% | |
| Q3 2020 | +5.8% | -1.4% | +9.9% | |
| Q2 2020 | +11.5% | +14.9% | +20.6% | |
| Q1 2020 | -17.8% | -12.8% | -8.3% | |
| Q4 2019 | -8.4% | -12.7% | -17.6% | |
| Q3 2019 | +1.5% | +4.3% | +24.1% | |
| Q2 2019 | +11.2% | +17.3% | +30.3% | |
| Q1 2019 | +13.0% | +10.0% | +22.7% | |
| Q4 2018 | +4.0% | -2.5% | -10.8% | |
| Q3 2018 | -23.6% | -22.9% | -29.6% | |
| Q2 2018 | -6.7% | -9.2% | +6.8% | |
| Q1 2018 | +11.2% | +14.3% | +25.7% | |
| Q4 2017 | -10.4% | -1.9% | +1.9% | |
| Q3 2017 | +7.5% | +19.3% | +4.7% | |
| Q2 2017 | +4.3% | +2.3% | +2.1% | |
| Q1 2017 | +3.2% | +8.2% | +16.4% | |
| Q4 2016 | -3.5% | +6.3% | -1.4% | |
| Q3 2016 | +13.4% | +21.8% | +34.5% | |
| Q2 2016 | -34.3% | -31.6% | -31.6% | |
| Q1 2016 | +2.3% | — | — | |
| Q4 2015 | +24.7% | — | — | |
| Q3 2015 | +22.3% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro